Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

Phase 4

Completed

Brief Summary: This open-label extension study will evaluate the long-term safety of glatiramer acetate and its effect on the neurologic course of participants with relapsing-remitting multiple sclerosis (RRMS). Participants have scheduled visits every 3 months to assess glatiramer acetate safety and their Multiple Sclerosis (MS) status.

Recruitment & Eligibility

Inclusion Criteria

Participants must have participated (been randomized) in the Copaxone double-blind placebo-controlled study 01-9001 and/or the double-placebo-controlled extension study 01-9001E.
Participants could be male or female. Women of childbearing potential must have practiced an acceptable method of birth control.
Participants must have completed the scheduled termination visit for Amendment 12 (Month 264).
Participants must have signed an approved informed consent form (ICF) prior to continuing in the study extension or at the first visit in the extension (Month 264 which corresponds to the termination visit of Amendment 12).
Participants must have been psychologically and physically stable to participate in the trial as judged by the investigator.
All participants enrolled in this extension study were required to have the following study-specific baseline characteristics prior to entry to Study 01-9001: a diagnosis of RRMS as defined by Poser et al 1983, at least 2 clearly identified relapses and remissions in the 2-year period prior to study entry, ambulatory with a Kurtzke EDSS score of 0 to 5.0 inclusive, and a stable neurologic state for at least 30 days prior to study entry.

Exclusion Criteria

Pregnancy or lactation.
Medical or psychiatric conditions that affect the participant's ability to give informed consent or complete the study.
Inability to self-administer subcutaneous medication or lack of another responsible individual to administer the study preparation daily.
Use of approved MS therapies including interferons, experimental MS therapies, or previous immunosuppressive therapy with cytotoxic chemotherapy (azathioprine, cyclophosphamide, or cyclosporine).

Arm && Interventions

Group	Intervention	Description
Glatiramer Acetate: Delayed Start	Glatiramer acetate	Participants who were originally randomized to the placebo group in the 01-9001 and/or the 01-9001E studies received glatiramer acetate 20 milligrams (mg) subcutaneous (SC) injection daily at the start of this study. After 18 July 2014 (protocol amendment 12), participants were offered the opportunity to continue treatment with glatiramer acetate 20 mg daily or switch to glatiramer acetate 40 mg three times weekly (TIW). The treatment continued for up to 288 months.
Glatiramer Acetate: Early Start	Glatiramer acetate	Participants who were originally randomized to the glatiramer acetate 20 mg group in the 01-9001 and/or the 01-9001E studies continued to receive glatiramer acetate 20 mg SC injection daily at the start of this study. After 18 July 2014 (protocol amendment 12), participants were offered the opportunity to continue treatment with glatiramer acetate 20 mg daily or switch to glatiramer acetate 40 mg TIW. The treatment continued for up to 288 months.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Adverse Events (AEs)	Baseline up to Month 288	An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. Any AEs included both serious and non-serious AEs. A summary of other non-serious AEs and all serious AEs, regardless of causality, is located in Reported AE section.
Change From Baseline in Kurtzke Expanded Disability Status Scale (EDSS) Score at Month 288	Baseline, Month 288	The EDSS uses an ordinal scale to assess neurologic impairment in Multiple Sclerosis based on a neurological examination. Scores in each of 7 functional systems (Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, and Cerebral) and an ambulation score were combined to determine the total EDSS score, ranging from 0 (normal) to 10 (death due to Multiple Sclerosis).

Secondary Outcome Measures

Name	Time	Method

Locations (11): Teva Investigational Site 009
🇺🇸
Los Angeles, California, United States
Teva Investigational Site 004
🇺🇸
Los Angeles, California, United States
Teva Investigational Site 008
🇺🇸
New Haven, Connecticut, United States
Teva Investigational Site 005
🇺🇸
Baltimore, Maryland, United States
Teva Investigational Site 003
🇺🇸
Detroit, Michigan, United States
Teva Investigational Site 002
🇺🇸
Albuquerque, New Mexico, United States
Teva Investigational Site 007
🇺🇸
Rochester, New York, United States
Teva Investigational Site 001
🇺🇸
Philadelphia, Pennsylvania, United States
Teva Investigational Site 010
🇺🇸
Houston, Texas, United States
Teva Investigational Site 006
🇺🇸
Salt Lake City, Utah, United States
Teva Investigational Site 011
🇺🇸
Madison, Wisconsin, United States